On what date did the absorption-type merger between Clayce Corporation and Satt Corporation become effective?

The absorption-type merger between Clayce Corporation and Satt Corporation was completed on April 1, 2026, with Clayce as the surviving entity and Satt as the dissolving company.

What is the headquarters location of Carenet Clinical Research Operations, Inc. after the merger?

Carenet Clinical Research Operations, Inc. is located at Capital Akasaka Building 6F, 1-7-19 Akasaka, Minato-ku, Tokyo, following the organizational restructuring and name change on April 1, 2026.

What are the primary business objectives of Carenet Clinical Research Operations, Inc. after the merger?

Carenet Clinical Research Operations, Inc. aims to provide advanced CRO services from clinical development to clinical research by leveraging the combined expertise of Clayce, Satt, and Carenet's physician network and media platforms.

What strategic rationale led Carenet Co., Ltd. to merge Clayce Corporation and Satt Corporation?

Carenet Co., Ltd. merged Clayce and Satt to integrate management resources, enhance agility, and build a stronger support system for pharmaceutical companies and medical institutions amid increasing digitalization in clinical research and development.

AI News NQ Analysis

Announcement of the Establishment of Carenet Clinical Research Operations, Inc. (Abbreviation: CCRO)

NQ Score 100/100

AI Summary (NQ-processed)

Carenet Co., Ltd.'s consolidated subsidiaries, Clayce Corporation and Satt Corporation, have completed an absorption-type merger with Clayce as the surviving company, effective April 1, 2026. Concurrently, the surviving company, Clayce, has changed its trade name to Carenet Clinical Research Operations, Inc. (CCRO). The new entity aims to provide advanced CRO services covering clinical development and clinical research by leveraging the expertise of both companies and Carenet's physician member and media platforms.

AI analysis data is not yet available.

Frequently Asked Questions

Q: What is the new trade name of the surviving company after the merger between Clayce Corporation and Satt Corporation?: A: The surviving company, Clayce Corporation, changed its trade name to Carenet Clinical Research Operations, Inc. (abbreviation: CCRO) on April 1, 2026, following the absorption-type merger with Satt Corporation.
Q: On what date did the absorption-type merger between Clayce Corporation and Satt Corporation become effective?: A: The absorption-type merger between Clayce Corporation and Satt Corporation was completed on April 1, 2026, with Clayce as the surviving entity and Satt as the dissolving company.
Q: What is the headquarters location of Carenet Clinical Research Operations, Inc. after the merger?: A: Carenet Clinical Research Operations, Inc. is located at Capital Akasaka Building 6F, 1-7-19 Akasaka, Minato-ku, Tokyo, following the organizational restructuring and name change on April 1, 2026.
Q: What are the primary business objectives of Carenet Clinical Research Operations, Inc. after the merger?: A: Carenet Clinical Research Operations, Inc. aims to provide advanced CRO services from clinical development to clinical research by leveraging the combined expertise of Clayce, Satt, and Carenet's physician network and media platforms.
Q: What strategic rationale led Carenet Co., Ltd. to merge Clayce Corporation and Satt Corporation?: A: Carenet Co., Ltd. merged Clayce and Satt to integrate management resources, enhance agility, and build a stronger support system for pharmaceutical companies and medical institutions amid increasing digitalization in clinical research and development.